#1 Clinical Trials Search in Europe

Ondansetron Hydrochloride Dihydrate

This article discusses clinical trials investigating the use of Ondansetron Hydrochloride Dihydrate, a medication commonly used to prevent nausea and vomiting. The trials explore its potential applications in different medical conditions, including colorectal cancer, gastroenteropancreatic neuroendocrine tumors, and opioid-induced respiratory depression. These studies aim to evaluate the drug’s efficacy, safety, and potential new uses in combination with other treatments.

Table of Contents

What is Ondansetron Hydrochloride Dihydrate?

Ondansetron Hydrochloride Dihydrate is the active ingredient in several medications used to prevent nausea and vomiting. It belongs to a class of drugs called serotonin 5-HT3 receptor antagonists[1]. These medications work by blocking the action of serotonin, a natural substance in the body that can cause nausea and vomiting.

What is it used for?

Ondansetron is primarily used to prevent and treat nausea and vomiting associated with various conditions and treatments, including:

  • Chemotherapy-induced nausea and vomiting
  • Radiation therapy-induced nausea and vomiting
  • Post-operative nausea and vomiting
  • In some cases, severe nausea and vomiting during pregnancy (although this use is off-label and should only be under strict medical supervision)

It’s important to note that ondansetron is often used as an auxiliary medication in various medical procedures and treatments to improve patient comfort and treatment adherence[2].

How is it administered?

Ondansetron Hydrochloride Dihydrate can be administered in several forms:

  • Oral tablets (e.g., Ondansetron Bluefish 8 mg tablets, filmdrasjerte)[2]
  • Intravenous (IV) injection (e.g., Zofran 4 Injectie)[4]
  • Film-coated tablets (e.g., ZOPHREN 8 mg, comprimé pelliculé)[3]

The method of administration depends on the specific medical situation and the patient’s condition. For instance, IV administration might be preferred in hospital settings or for patients undergoing chemotherapy, while oral tablets are more common for outpatient use.

Dosage Information

The dosage of ondansetron varies depending on the specific product, the condition being treated, and individual patient factors. However, some general guidelines based on the available information include:

  • For oral tablets: The maximum daily dose is typically 8 mg, with a total treatment amount of up to 960 mg over a 30-day period[2].
  • For intravenous use: The maximum daily dose is usually 8 mg, with a total treatment amount of up to 32 mg over a 4-day period[4].
  • For film-coated tablets: The maximum daily dose is 8 mg, with a total treatment amount of up to 40 mg over a 5-day period[3].

It’s crucial to follow the dosage instructions provided by your healthcare provider, as they will consider your specific medical needs and condition.

Potential Side Effects

While ondansetron is generally well-tolerated, like all medications, it can cause side effects. Common side effects may include:

  • Headache
  • Constipation
  • Dizziness
  • Fatigue

More serious side effects, though rare, can occur. These may include allergic reactions, changes in heart rhythm, or serotonin syndrome (when used with other medications that increase serotonin levels). Always inform your healthcare provider of any side effects you experience.

Precautions and Considerations

Before using ondansetron, inform your healthcare provider if you:

  • Have any allergies, especially to ondansetron or other medications
  • Have a history of heart problems, particularly relating to heart rhythm
  • Are pregnant or breastfeeding
  • Have liver problems
  • Are taking other medications, including over-the-counter drugs and supplements

Your healthcare provider will consider these factors when determining if ondansetron is appropriate for you and in deciding the correct dosage.

Ongoing Research

Ondansetron continues to be studied in various clinical settings. Current research includes its use in:

  • Treatment of opioid-induced respiratory depression: A study is investigating the use of ondansetron alongside other medications to reverse respiratory depression caused by opioids[4].
  • Management of nausea and vomiting in patients with neuroendocrine tumors: Ondansetron is being used as an auxiliary medication in studies involving patients with gastroenteropancreatic neuroendocrine tumors[3].

These ongoing studies may provide new insights into additional uses and benefits of ondansetron in the future.

Trial Name Medical Condition Main Objective Ondansetron Administration
METIMMOX-2 Metastatic colorectal cancer To determine progression-free survival of repeat sequential treatment with oxaliplatin-based chemotherapy and an immune checkpoint inhibitor Oral tablets or intravenous injection/infusion
LUTARTERIAL Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) with liver metastases To evaluate 68Ga-DOTA-peptides uptake in liver metastases after intra-hepatic and intravenous injections Oral tablets or intravenous injection
ROAR Opioid-induced respiratory depression To describe the pharmacokinetics and pharmacodynamics of intravenous fentanyl and sufentanil on ventilation and the ability of naloxone and nalmefene to reverse respiratory depression Intravenous injection

FAQ

  • What is Ondansetron Hydrochloride Dihydrate? Ondansetron Hydrochloride Dihydrate is a medication primarily used to prevent nausea and vomiting. It belongs to a class of drugs called serotonin 5-HT3 receptor antagonists.
  • In which medical conditions is Ondansetron being studied? The clinical trials are exploring the use of Ondansetron in colorectal cancer, gastroenteropancreatic neuroendocrine tumors (GEP-NETs), and as a supportive medication in studies involving opioid-induced respiratory depression.
  • How is Ondansetron administered in these trials? Ondansetron is administered in various forms depending on the trial, including oral tablets, intravenous injections, and intravenous infusions.
  • What are the main objectives of these clinical trials? The main objectives vary by trial but generally include evaluating the safety and efficacy of Ondansetron in combination with other treatments, assessing its impact on patient outcomes, and exploring its potential new applications in different medical conditions.
  • Are there any specific side effects being monitored in these trials? While specific side effects are not detailed in the provided information, the trials are monitoring the overall safety profile of Ondansetron, including any adverse events that may occur during treatment.

Ongoing Clinical Trials on Ondansetron Hydrochloride Dihydrate

  • Study of Intra-Arterial Infusion of Lutetium (177Lu) Oxodotreotide for Adults with Gastroenteropancreatic Neuroendocrine Tumors with Liver Metastases

    Recruiting

    2 1 1 1
    Investigated drugs:
    France

  • Study on Reversing Opioid-Induced Breathing Problems Using Naloxone and Nalmefene in Healthy Volunteers and Opioid Users

    Not recruiting

    3 1 1 1
    Investigated drugs:
    The Netherlands

  • Study of Lurbinectedin and Doxorubicin for First-line Treatment in Patients with Metastatic Leiomyosarcoma

    Not recruiting

    3 1 1 1
    Investigated drugs:
    Austria Belgium France Germany Italy The Netherlands +3

  • Study of Oxaliplatin and Nivolumab for Patients with Metastatic Colorectal Cancer

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Norway

Glossary

  • Ondansetron Hydrochloride Dihydrate: A medication used to prevent nausea and vomiting, belonging to a class of drugs called serotonin 5-HT3 receptor antagonists.
  • Colorectal cancer: A type of cancer that starts in the colon or rectum, which are parts of the large intestine.
  • Gastroenteropancreatic neuroendocrine tumors (GEP-NETs): Rare tumors that develop in the digestive system, including the stomach, intestines, and pancreas.
  • Metastatic: Referring to cancer that has spread from its original site to other parts of the body.
  • RECIST: Response Evaluation Criteria in Solid Tumors, a set of rules used to measure how well a cancer patient responds to treatment.
  • Progression-free survival (PFS): The length of time during and after treatment that a patient lives with the disease but it does not get worse.
  • Overall survival (OS): The length of time from the start of treatment or diagnosis that patients are still alive.
  • Adverse events: Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Pharmacodynamics (PD): The study of the biochemical and physiological effects of drugs on the body and the mechanisms of drug action.
  • Opioid-induced respiratory depression: A potentially serious side effect of opioid medications where breathing becomes slow and ineffective.
  • Intranasal: Administered through the nose.
  • Intravenous: Administered directly into a vein.
  • Body Mass Index (BMI): A measure that uses your height and weight to work out if your weight is healthy.
  • Glomerular filtration rate: A test used to check how well the kidneys are working.

References

  1. http://clinicaltrials.eu/trial/study-of-oxaliplatin-and-nivolumab-for-patients-with-metastatic-colorectal-cancer/
  2. http://clinicaltrials.eu/trial/study-of-lurbinectedin-and-doxorubicin-for-first-line-treatment-in-patients-with-metastatic-leiomyosarcoma/
  3. http://clinicaltrials.eu/trial/study-of-intra-arterial-infusion-of-lutetium-177lu-oxodotreotide-for-adults-with-gastroenteropancreatic-neuroendocrine-tumors-with-liver-metastases/
  4. http://clinicaltrials.eu/trial-id/2024-518041-16-00